A.ataract needs to be removed only when vision loss interferes with your everyday activities, such as driving, reading, or watching TV. In the United States, age-related lens changes have been reported in 42% between the ages of 52 and 64, 54 60% between the ages 65 and 74, 55 and 91% between the ages of 75 and 85. 54 Cataracts affect nearly 22 million Americans age 40 and older. Before cataract surgery, your doctor may ask you to temporarily stop taking certain medications that increase the risk of bleeding during surgery. Avoid rubbing or pressing on your eye. The sooner you get treatment, the more likely you will regain good vision. American Journal of Preventive Medicine. Mayo Clinic, Rochester, Finn. As the protein loses function, small peptides, made of 10 to 15 amino acids, start forming and accelerate cataract formation in the eye, a study revealed .
American.ournal.f Preventive Medicine. The lens also adjusts the eye’s focus, letting us see things clearly both up close and far away. The lens must be clear for the retina to receive a sharp image. But researchers worldwide have identified factors that may cause cataracts or are associated with cataract development. June 11, 2013. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. Access to eye care in many countries in this region is limited. 57 See also: Cataract surgery § History The first references to cataracts and their treatment in Ancient Rome are found in 29 AD in De medicinal, the work of the Latin encyclopedist Zulus Cornelius Celsius . 58 Archaeological evidence of eye surgery in the Roman era also exists. 59 Other early accounts are found in Sanskrit . The most common symptom of cataracts is the noticeable blurring and worsening of vision. Medically Reviewed by a Doctor on 2/18/2015 Do Supplements Give Athletes an Edge? http://toughaydenhenry.adafire.org/2016/11/04/some-basic-questions-for-intelligent-astigmatism-programs/Environmental factors, including toxins, radiation, and ultraviolet light, have cumulative effects, which are worsened by the loss of protective and restorative mechanisms due to alterations in gene expression and chemical processes within the eye. 12 Blunt trauma causes swelling, thickening, and whitening of the lens fibbers. The surgical removal of cataracts is a very common procedure and is highly effective roughly 90 percent of the time, according to the National Eye Institute. General anaesthesia breathing tube and fully asleep is rarely used with cataract surgery. http://www.expertselfpublishing.com/dylanyoungrock/2016/11/01/top-insights-for-2015-on-rapid-methods-for-vitrectomy/
( EYEG ) (EyeGate or the Company), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced financial results for the three-month period ended September 30, 2016, and provided an update on recent corporate and operational activities. Third Quarter 2016 and Recent Business Highlights: Reported positive top-line data from Phase 1b/2a clinical trial of the EGP-437 combination product for treatment of post-operative inflammation and pain in cataract surgery patients; Received additional milestone payment from Valeant Pharmaceuticals International, Inc. (Valeant) for EGP-437 in uveitis; Continued enrolling patients in confirmatory Phase 3 clinical trial of the EGP-437 combination product targeting non-infectious anterior uveitis; Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense to continue development of cross-linked thiolated hyaluronic acid (CMHA-S) for use as an ocular bandage film; We made continued, significant progress in the third quarter as we further advanced both the EGP-437 combination product and the EyeGate OBG programs, and positioned the Company to achieve key milestones over the next 12 months, said Stephen From, President and Chief Executive Officer of EyeGate. The three new cohorts in our Phase 1b/2a trial of the EGP-437 combination product in cataract surgery patients have progressed according to plan and we remain on track to report top-line data from these cohorts in the fourth quarter of 2016. We believe that these additional cohorts, which are evaluating additional doses and dosing regimens of EGP-437, will allow us to build upon the positive top-line data we reported in August and to initiate a randomized, placebo-controlled trial of EGP-437 in cataract surgery patients in the first quarter of 2017. In addition, patient enrollment in the confirmatory Phase 3 trial of the EGP-437 combination product in uveitis progressed, and the Company earned another milestone payment under our worldwide licensing agreement with Valeant for this indication. We continue to target an NDA submission for the EGP-437 combination product in uveitis in late 2017. Mr. From continued, We are extremely pleased with the progress we have made on the EGP-437 combination product, and have also taken important steps forward in the development of our CHMA-S platform and its lead product, the EyeGate OBG. We are on track for a meeting with the FDA and expect to initiate our first CMHA-S clinical trial, in corneal repair, by the end of the year. Additionally, we received the second year of funding of our Phase II SBIR grant from the U.S.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/eyegate-pharmaceuticals-reports-third-quarter-132000500.html